91Ó°ÊÓ

When testing the effectiveness of a new vaccine, it's essential to establish hypotheses clearly. The null hypothesis, often denoted as \(H_0\), generally represents the status quo or a statement of no effect. In this case, the null hypothesis would assert that the new vaccine does not improve the likelihood of avoiding the disease compared to the existing vaccine. Mathematically, this is expressed as \(H_0: p \geq 0.3\), where \(p\) represents the probability of contracting the disease after receiving the new vaccine.

Conversely, the alternative hypothesis, represented by \(H_a\), proposes a different outcome from the null. Here, \(H_a: p < 0.3\) suggests that the new vaccine results in a lower probability of contracting the disease, indicating it is more effective than the current option. Formulating these hypotheses helps set a focused direction for the hypothesis test.

The significance level, denoted as \( \alpha \), is a critical component of hypothesis testing. It defines the probability of rejecting the null hypothesis when it is actually true, commonly known as making a Type I error. A lower significance level indicates a more stringent test, reducing the likelihood of incorrectly claiming the new vaccine is more effective.

In the case of the 100-person study, the significance level is determined by the likelihood that 84 or more out of 100 people, don't contract the disease when the actual probability is 0.3. This level, calculated using binomial distribution properties, turns out to be approximately 0.028. Meanwhile, for the 20-person case, the significance level is based on the probability that fewer than 3 out of 20 people contract the disease, equating to about 0.009. Both values reflect the tests' strictness in minimizing false positives.

The binomial distribution is a statistical tool used to model the number of successes in a fixed number of trials, each with a constant probability of success. In vaccine efficacy studies, each trial represents an individual receiving the vaccine, and success is if the person does not contract the disease.

The distribution is defined by two parameters: \(n\), the number of trials, and \(p\), the probability of success in each trial. Using the cumulative distribution function for the binomial distribution, one can calculate the probabilities needed to assess the significance level. For the 100-person study where \(n = 100\) and \(p = 0.3\), and the 20-person study with \(n = 20\) and \(p = 0.3\), this function helps determine the likelihood of observing our sample results if the null hypothesis were true.

Vaccine efficacy measures how well a vaccine works at preventing a disease in a real-world population. For a vaccine deemed effective, it should significantly decrease the chances of contracting the disease compared to a control group.

In this exercise, testing the new vaccine involves comparing its efficacy against an existing vaccine with a success rate of 70% (i.e., 30% are still at risk). Determining vaccine efficacy scientifically requires careful statistical analysis, such as using hypothesis testing to ascertain whether a new vaccine provides a statistically significant improvement. Understanding terms like null and alternative hypotheses, significance levels, and the appropriate use of binomial distribution is essential for interpreting the results of vaccine efficacy studies.